期刊文献+

人β干扰素基因的改构及其融合表达和纯化 被引量:2

Expression and purification of human interferon-β after gene modification
原文传递
导出
摘要 目的 :通过基因改构来提高人 β干扰素基因原核表达产物的稳定性和比活性。 方法 :用RT_PCR法从人外周血淋巴细胞中获得人 β干扰素基因。定点突变后 ,克隆至表达载体pGEX_2T。IPTG诱导该基因的表达 ,亲和层析和原位裂解法纯化表达产物。结果 :获得大量纯化产物 ,且稳定性和活性获得极大提高。结论 :基因改构可以提高人 Objective:To improve the stability and the activity of human interferon_β through gene modification.Methods:Human interferon_β gene was cloned from a donor′s peripheral blood lymphocytes via extraction of total RNA, reverse transcription and nest_PCR. After site_directed mutagenesis, the gene was cloned into expression vector pGEX_2T. The modified gene was expressed by IPTG induction and purified by affinity chromatography and cleavage in place.Results:Large amount of purified gene product was obtained and its stability and activity were improved tremendously.Conclusion:The stability and activity of procaryotically expressed human interferon_β can be improved through gene modification.
出处 《军事医学科学院院刊》 CSCD 北大核心 2002年第1期21-23,共3页 Bulletin of the Academy of Military Medical Sciences
关键词 Β干扰素 基因改构 稳定性 比活性 RT-PCR Β干扰素 融合表达 纯化 interferon_β gene modification fused expression purification
  • 相关文献

参考文献2

共引文献9

同被引文献17

  • 1史艳秋,陈畅,顾黎,邹思湘,宋静,王鹏.重组人β干扰素在DHFR^--CHO细胞中的高效表达[J].中国生化药物杂志,2006,27(3):129-133. 被引量:7
  • 2雷楗勇,张莲芬,杨健良,金坚.人β干扰素-血清白蛋白融合蛋白在毕赤酵母中的分泌表达[J].中国生物工程杂志,2006,26(7):13-18. 被引量:20
  • 3Thoenen H, Barde YA. Physiology of nerve growth factor [ J]. Physiol Rev, 1980, 60(4) : 1284 - 1335.
  • 4Levi-Montalcini R, Skaper SD, Toso RD, et al. Nerve growth factor:from neurotrophin to neurokine [J]. Trends Neurosci, 1996, 19(11):514 - 520.
  • 5Lindsay RM. Neurotrophic factors: from molecule to man [J]. Trends Neurosci, 1994, 17(5):182- 189.
  • 6Walsh G.Biopharmaceutical benchmarks[J].Nat Biotechnol,2006,24(7):769-776.
  • 7Tuna Y,Baar O,Dikici H,et al.Rapid onset of ulcerativecolitis after treatment with interferonβ1ain a patient with multiplesclerosis[J].J Crohn’s Colitis,2011,5(1):75-76.
  • 8Lindsey JW,Scott TF,Lynch SG,et al.The CombiRx trial ofcombined therapy with interferon and glatiramer acetate in relapsingremitting MS:Design and baseline characteristics[J].MultiSclerosis Relat Disor,2012,1(2):81-86.
  • 9Neetu A,Edward K.Cost-effectiveness of early initiation offingolimod versus delayed initiation after 1year of intramuscularinterferon beta-1ain patients with multiple sclerosis[J].ClinTher,2012,34(7):1583-1590.
  • 10Mark DF,Lu SD,Creasey AA,et al.Site-specificmutagenesis of human fibroblast interferon gene[J].Proc NatlAcad Sci,1984,81(18):5662-5666.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部